NCT03654612 (Y-HR2017-025) is a Phase 1, PHASE2 clinical trial of Apatinib in Head and Neck Cancer, sponsored by China International Medical Foundation.

Who is sponsoring NCT03654612?

NCT03654612 is sponsored by China International Medical Foundation.

What drugs are being tested in NCT03654612?

Interventions in NCT03654612: Apatinib.

What condition does NCT03654612 study?

NCT03654612 studies Head and Neck Cancer.

Is NCT03654612 still recruiting?

NCT03654612 is currently status unknown. Last updated 18 October 2018.

Last reviewed 2018-10-18 · How we verify

NCT03654612: Y-HR2017-025

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies

Status unknown Phase 1, PHASE2 Last updated 18 October 2018

What this trial tests

Phase 1, PHASE2 trial testing Apatinib in Head and Neck Cancer in 30 participants. Status unknown.

Timeline

16 October 2018

Primary endpoint
1 March 2020

1 September 2021

Quick facts

Lead sponsor	China International Medical Foundation
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	16 October 2018
Primary completion	1 March 2020
Estimated completion	1 September 2021
Sites	1 location across China

Drugs / interventions tested

Apatinib (Apatinib) — full drug profile →

Conditions studied

Head and Neck Cancer — all drugs for Head and Neck Cancer →

Sponsor

China International Medical Foundation

Who can join

Adults 18 to 70, any sex, with Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This open, single-arm, exploratory study looked at the efficacy and safety of apatinib in combination with S-1 as second-line treatment of advanced head and neck malignancies.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

New insights into RAS in head and neck cancer.
Jagadeeshan S, Novoplansky OZ, Cohen O, Kurth I, et al · · 2023 · cited 8× · PMID 37619805 · DOI 10.1016/j.bbcan.2023.188963

Verify or expand the search:

Other trials of Apatinib

Trials testing the same drug.

NCT07309419 — A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunothera · Phase 2, PHASE3 · not yet recruiting
NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
NCT07031154 — A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Rese · Phase 2 · not yet recruiting
NCT07294664 — PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer · Phase 2 · recruiting
NCT06893887 — Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma · NA · recruiting

Other recruiting trials for Head and Neck Cancer

Currently open trials in the same condition.

NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03654612 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by China International Medical Foundation
Last refreshed: 18 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03654612.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing